Demant stock holds near 52-week high as investors weigh first-half performance

Published on 09/21/2026 at 14:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Demant stock was quoted at DKK 301.00 on Nasdaq Copenhagen as of September 20, 2026, matching its 52-week high and marking a rise of about 72.0% from the 52-week low of DKK 175.00. The latest first-half figures show solid revenue and earnings momentum for the hearing-care group.

Fotorealistische Szene einer Hörgeräte-Fertigung in modernem Reinraum, Medizintechnik-Industrie — Fotorealistisches Bild zeigt Demant A/S, ISIN DK0010268440, mit Hörgeräte-Fertigung und modernem Reinraum in Dänemark, Illustration mit AI erstellt.

Demant stock (ISIN DK0010268440) was quoted at DKK 301.00 on Nasdaq Copenhagen as of September 20, 2026, matching its 52-week high and standing far above the 52-week low of DKK 175.00, a gain of about 72.0% over the past year.

Stock trades at the top of its 52-week range

At the closing price of DKK 301.00 on Nasdaq Copenhagen on September 20, 2026, Demant stock stood exactly at its 52-week high of DKK 301.00 and well above the 52-week low of DKK 175.00, underscoring the strong recovery in the share price over the period.

On that trading day, the shares rose about 0.60% from a prior close of DKK 299.20, with an intraday range between DKK 297.40 and DKK 301.00, showing a relatively tight but upward-trending session for investors.

First-half figures underpin valuation

Demant A/S reported solid first-half 2026 results with revenue and earnings growth compared with the prior-year period, providing fundamental support to the elevated share price level.

In the first half of 2026, the company increased revenue versus the first half of 2025, while operating profit and margin improved, reflecting stronger demand for hearing instruments and related services.

Market capitalization reflects higher expectations

Based on the closing price of DKK 301.00 on September 20, 2026, Demant’s market capitalization stood at about DKK 53,000,000,000, illustrating how the stock’s climb toward the 52-week high has lifted the company’s overall market value.

For investors, the combination of a share price at the 52-week high, a roughly 72.0% rise from the 52-week low of DKK 175.00, and improving first-half 2026 fundamentals suggests that expectations for continued growth in the core hearing-care business remain firmly embedded in the valuation.